Total Sales Grow 20% Year-Over-Year
U.S. Visian ICL Sales Increase Year-Over-Year
Cost Reduction Efforts Show Continued Results
Company Ends the Quarter with $10.5 Million in Cash
MONROVIA, Calif., May 6 /PRNewswire-FirstCall/ -- STAAR Surgical
Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of
minimally invasive ophthalmic products, today reported good progress during
its first quarter ended March 28, 2008.
Recent Highlights
Corporate Highlights
-- Total sales grew 20% year-over-year to $17,960,000
-- Total international sales growth of 37% year-over-year to
$13,436,000
-- Cost reduction programs focused on U.S. operations generated results
-- Strong management of cash resources continued: $10,522,000 on hand
as of March 28 versus $10,895,000 as of December 28, 2007
Visian ICL Highlights
-- Global Visian ICL sales increased by 18%
-- International ICL sales growth of 23%
-- Approval from China's SFDA to market the Toric ICL and Hyperopic ICL
-- U.S. Visian ICL sales increased nine percent year-over-year with
even stronger growth to start Q2
-- Introduced new Visian ICL Growth Program(TM)
-- Increased consumer media coverage in key markets
-- Traffic on http://www.visianinfo.com more than doubled in March and
April compared to 2007
-- Media focus on complications of the LASIK refractive surgery
IOL Highlights
-- Global cataract sales increased by 22%
-- Strategic roadmap developed to re
'/>"/>
| SOURCE STAAR Surgical Company Copyright©2008 PR Newswire. All rights reserved |